Dexcom (NSDQ:DXCM) announced today that it plans to launch its G7 15 Day continuous glucose monitor (CGM) in the U.S. next ...

Dexcom announced the Dexcom G7 15 Day Continuous Glucose Monitoring System for people over the age of 18 with diabetes will ...

DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the Dexcom G7 15 Day Continuous Glucose ...

Dexcom’s “Smart Basal” has received FDA clearance for people with type 2 diabetes using long-acting insulin. The feature will ...

With more than 10 years of pioneering CGM market leadership in AID integration, Dexcom is the most studied CGM brand with AID capabilities and the clear choice for powering AID systems 3,4 The ...

It takes two: After making its commercial debut early this year, Dexcom’s latest continuous glucose monitor is wrapping up 2023 by connecting with its first automated insulin pump partner, courtesy of ...

DexCom, Inc. DXCM announced that its latest G7 continuous glucose monitoring (CGM) system can now connect with Tandem Diabetes Care's t:slim X2 insulin pump featuring Control-IQ technology. This ...

(NASDAQ: DXCM), the global leader in glucose biosensing, announced today the FDA has cleared Dexcom Smart Basal, the first and only CGM-integrated basal insulin dosing optimizer designed for adults ...

* Dexcom G7 can complete warmup within 30 minutes, whereas other CGM brands require up to an hour or longer.†If your glucose alerts and readings from Dexcom G7 do not match symptoms or expectations, ...